Filing Flows › Alnylam Pharmaceuticals (ALNY) › Q3 2025
Alnylam Pharmaceuticals (ALNY) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 30, 2025
Alnylam Pharmaceuticals (ALNY) reported revenue of $1.2B for the third quarter 2025 (Q3 2025), +149% from a year earlier and +61% from the quarter before. Operating margin was 29.5%, net earnings $251M (20.1% of revenue).
Alnylam Pharmaceuticals, Q3 2025: revenue $1.2B (+149% year over year), operating margin 29.5%, net earnings $251M, operating cash flow $325M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2B | +61% | +149% |
| Operating profit | $368M | — | — |
| Net earnings | $251M | — | — |
| Operating cash flow | $325M | +111% | +644% |
| Free cash flow | $313M | +124% | +692% |
What changed
Revenue was $1.2B in Q3 2025, up 149% year over year and up 61% from the previous quarter. AMVUTTRA was the largest line at 55% of revenue. AMVUTTRA added $0.43B year over year (up 165%), 57% of the total change. ONPATTRO declined 22%.
Operating profit was $0.37B, a 29.5% margin (up 44.8 points year over year). Total costs grew 52% against revenue growth of 149%. The fastest-growing cost line was Cost of revenue (+141%). Net earnings were $0.25B. The effective tax rate was -5.1%.
Operating cash flow was $0.33B (up 644% year over year), 129% of net earnings. Non-cash charges added back $0.01B of depreciation and amortization and $0.11B of share-based compensation. Working capital and other items used $0.05B. Capital expenditures of $0.01B left free cash flow of $0.31B.
Questions
What was Alnylam Pharmaceuticals' revenue in the third quarter 2025?
Alnylam Pharmaceuticals (ALNY) reported revenue of $1.2B for the third quarter 2025 (Q3 2025), +149% from a year earlier and +61% from the quarter before.
Was Alnylam Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $368M (29.5% of revenue) and net earnings $251M.